Drugs / Vopratelimab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04319224 | Mar 2020 → Jan 2023 | cancer | Jounce Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02904226 | Aug 2016 → Jul 2020 | cancer | Jounce Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04549025 | Oct 2020 → Apr 2024 | non-small cell lung carcinoma | Jounce Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03989362 | Jun 2019 → Mar 2022 | cancer | Jounce Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vopratelimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04319224 ↗ |
| Known as | Anti-icos agonist mab jtx-2011 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298004 ↗ |
| Known as | JTX-2011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02904226 ↗ |
| Action | Activate | “JTX-2011 is an agonist monoclonal antibody” NCT02904226 ↗ |
| Modality | Monoclonal antibody | “JTX-2011 is an agonist monoclonal antibody” NCT02904226 ↗ |
| Route | Intravenous | “by intravenous (IV) infusion” NCT02904226 ↗ |
| Target | ICOS | “specifically binds to the Inducible CO-Stimulator of T cells (ICOS)” NCT02904226 ↗ |